BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34800987)

  • 21. Assessment of a Revised Management Strategy for Patients With Intraductal Papillary Mucinous Neoplasms Involving the Main Pancreatic Duct.
    Sugimoto M; Elliott IA; Nguyen AH; Kim S; Muthusamy VR; Watson R; Hines OJ; Dawson DW; Reber HA; Donahue TR
    JAMA Surg; 2017 Jan; 152(1):e163349. PubMed ID: 27829085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonoperative management of main pancreatic duct-involved intraductal papillary mucinous neoplasm might be indicated in select patients.
    Roch AM; DeWitt JM; Al-Haddad MA; Schmidt CM; Ceppa EP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    J Am Coll Surg; 2014 Jul; 219(1):122-9. PubMed ID: 24862887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pancreatic juice cytology as sensitive test for detecting pancreatic malignancy in intraductal papillary mucinous neoplasm of the pancreas without mural nodule.
    Kawada N; Uehara H; Nagata S; Tomita Y; Nakamura H
    Pancreatology; 2016; 16(5):853-8. PubMed ID: 27459913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Moris D; Damaskos C; Spartalis E; Papalampros A; Vernadakis S; Dimitroulis D; Griniatsos J; Felekouras E; Nikiteas N
    Anticancer Res; 2017 May; 37(5):2185-2194. PubMed ID: 28476781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes.
    Ridtitid W; DeWitt JM; Schmidt CM; Roch A; Stuart JS; Sherman S; Al-Haddad MA
    Gastrointest Endosc; 2016 Sep; 84(3):436-45. PubMed ID: 26905937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can contrast-enhanced harmonic endoscopic ultrasonography accurately diagnose main pancreatic duct involvement in intraductal papillary mucinous neoplasms?
    Ohno E; Kawashima H; Ishikawa T; Iida T; Suzuki H; Uetsuki K; Yashika J; Yamada K; Yoshikawa M; Gibo N; Aoki T; Kataoka K; Mori H; Hirooka Y; Fujishiro M
    Pancreatology; 2020 Jul; 20(5):887-894. PubMed ID: 32651080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Noninvasive risk stratification of intraductal papillary mucinous neoplasia with malignant potential by serum apolipoprotein-A2-isoforms.
    Felix K; Honda K; Nagashima K; Kashiro A; Takeuchi K; Kobayashi T; Hinterkopf S; Gaida MM; Dang H; Brindl N; Kaiser J; Büchler MW; Strobel O
    Int J Cancer; 2022 Mar; 150(5):881-894. PubMed ID: 34778955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: implications of minimal involvement of the main pancreatic duct.
    Sahora K; Fernández-del Castillo C; Dong F; Marchegiani G; Thayer SP; Ferrone CR; Sahani DV; Brugge WR; Warshaw AL; Lillemoe KD; Mino-Kenudson M
    Surgery; 2014 Sep; 156(3):611-21. PubMed ID: 25081232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intraductal papillary mucinous neoplasms of the pancreas: differentiation of malignant and benign tumors by endoscopic ultrasound findings of mural nodules.
    Ohno E; Hirooka Y; Itoh A; Ishigami M; Katano Y; Ohmiya N; Niwa Y; Goto H
    Ann Surg; 2009 Apr; 249(4):628-34. PubMed ID: 19300203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Malignant potential and specific characteristics of pure main duct type intraductal papillary mucinous neoplasm.
    Fujita Y; Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Ueno M; Hayami S; Kobayashi R; Yanagisawa A; Yamaue H
    Eur J Surg Oncol; 2022 May; 48(5):1054-1061. PubMed ID: 34933794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can the location of the mural nodule indicate benign or malignant in branch duct-type intraductal papillary mucinous neoplasm of the pancreas?
    Niiya F; Ohike N; Norose T; Takano Y; Azami T; Kobayashi T; Maruoka N; Wakabayashi T; Matsuo K; Tanaka K; Nagahama M
    Pancreatology; 2020 Oct; 20(7):1379-1385. PubMed ID: 32873485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyst size indicates malignant transformation in branch duct intraductal papillary mucinous neoplasm of the pancreas without mural nodules.
    Sadakari Y; Ienaga J; Kobayashi K; Miyasaka Y; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Pancreas; 2010 Mar; 39(2):232-6. PubMed ID: 19752768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetes in intraductal papillary mucinous neoplasm of the pancreas and its association with malignancy.
    Zhou H; Chen X; Wang C; Lin T; Li X; Cui W; Wang J; Wang Y; Chen X
    J Surg Oncol; 2023 Mar; 127(4):625-632. PubMed ID: 36409079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pancreatic Fluid Interleukin-1β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia.
    Simpson RE; Yip-Schneider MT; Flick KF; Wu H; Colgate CL; Schmidt CM
    Pancreas; 2019 Sep; 48(8):1026-1031. PubMed ID: 31404023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of malignant and invasive predictors in branch duct type intraductal papillary mucinous neoplasms of the pancreas: a suggested scoring formula.
    Hwang DW; Jang JY; Lim CS; Lee SE; Yoon YS; Ahn YJ; Han HS; Kim SW; Kim SG; Yun YK; Han SS; Park SJ; Lim TJ; Kang KJ; Sim MS; Choi SH; Heo JS; Choi DW; Hur KY; Lee DS; Yun SS; Kim HJ; Cho CK; Kim HJ; Yu HC; Cho BH; Song IS
    J Korean Med Sci; 2011 Jun; 26(6):740-6. PubMed ID: 21655058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes.
    Pezzilli R; Calculli L; Melzi d'Eril G; Barassi A
    Hepatobiliary Pancreat Dis Int; 2016 Oct; 15(5):553-557. PubMed ID: 27733327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
    Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
    Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Permuth-Wey J; Chen DT; Fulp WJ; Yoder SJ; Zhang Y; Georgeades C; Husain K; Centeno BA; Magliocco AM; Coppola D; Malafa M
    Cancer Prev Res (Phila); 2015 Sep; 8(9):826-34. PubMed ID: 26314797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgical indication for intraductal papillary mucinous neoplasm without mural nodule ≥5 mm.
    Tsumura A; Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Hayami S; Ueno M; Yanagisawa A; Yamaue H
    Surgery; 2021 Feb; 169(2):388-395. PubMed ID: 32859391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum Anti-p53 Antibody Can Serve as a Predictive Marker for Histological Grade of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Hata T; Mizuma M; Motoi F; Iseki M; Omori Y; Hayashi H; Nakagawa K; Morikawa T; Kamei T; Naitoh T; Furukawa T; Unno M
    Pancreas; 2020 Jul; 49(6):768-773. PubMed ID: 32541631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.